RISE UP is the EHA 2026 Plenary Abstract Session study S102 evaluating mitapivat in sickle…
Browsing: biotech analysis
frontMIND is the EHA 2026 Plenary Abstract Session study S101 evaluating tafasitamab plus lenalidomide and…
MonumenTAL-3 is the Plenary Abstract Session study S100 evaluating talquetamab plus daratumumab with or without…
LB5006 / EHA-7249 is the EHA 2026 first-in-human study of LB2501, an in vivo CD19/CD20…
LB5007 / EHA-7241 is the RevSTAR-123 (AVC-201-01) study of switchable allogeneic CD123-directed CAR-T therapy in…
LB5003 / EHA-7251 is an EHA 2026 late-breaking study of BCMA CAR-T therapy in refractory…
SENTRY is an EHA 2026 late-breaking Phase 3 myelofibrosis study of selinexor plus ruxolitinib in…
ImmunoPRISM is an EHA 2026 LB5008 Phase 2 study of teclistamab versus lenalidomide-dexamethasone in high-risk…
HOVON156/AMLSG28-18/PASHA is EHA 2026 LB5005, a Phase 3 head-to-head study of gilteritinib versus midostaurin in…
BRUIN CLL-322 is EHA 2026 LB5001, a Phase 3 trial of fixed-duration pirtobrutinib plus venetoclax-rituximab…